Ticker LaunchIPO · EWTX
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (EWTX) priced its initial public offering on Mar 26, 2021 at $16.00 per share, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $761.1M. Wilson Sonsini advised the company and Cooley advised the underwriters.
Edgewise Therapeutics, Inc. is an early clinical-stage biopharmaceutical company, operating since 2017, developing precision medicines for rare neuromuscular diseases. Most of its product candidates were still in preclinical development at the time of its IPO.
- Status
- IPO
- Ticker
- EWTX
- Exchange
- Nasdaq Global Select
- Priced
- Mar 26, 2021
- IPO price
- $16.00
- Market cap at IPO price
- $761.1M
- First filed
- Mar 5, 2021
- Company counsel
- Wilson Sonsini
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- CO
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Mar 5, 2021
- Latest amendment Mar 24, 2021
- Final prospectus (424B4) Mar 26, 2021
- All filings on EDGAR CIK 1710072
Other Biotech & pharma IPOs in 2021
- Design Therapeutics, Inc.DSGN · Mar 26, 2021 · $240M
- ImageneBio, Inc.IKNA · Mar 26, 2021 · $125M
- LAVA Therapeutics NVLVTX · Mar 26, 2021 · $100.5M
- Universe Pharmaceuticals INCUPC · Mar 24, 2021 · $25M
- Finch Therapeutics Group, Inc.FNCH · Mar 22, 2021 · $127.5M
- Gain Therapeutics, Inc.GANX · Mar 22, 2021 · $40M